5.77
Y Mabs Therapeutics Inc stock is traded at $5.77, with a volume of 888.68K.
It is down -6.18% in the last 24 hours and down -16.26% over the past month.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$6.15
Open:
$6.08
24h Volume:
888.68K
Relative Volume:
2.32
Market Cap:
$258.43M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-11.78
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-3.83%
1M Performance:
-16.26%
6M Performance:
-48.53%
1Y Performance:
-55.99%
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
Name
Y Mabs Therapeutics Inc
Sector
Industry
Phone
212-847-9841
Address
230 PARK AVENUE, NEW YORK, NY
Compare YMAB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
YMAB
Y Mabs Therapeutics Inc
|
5.77 | 258.43M | 84.82M | -21.43M | -27.23M | -0.49 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
455.22 | 117.23B | 10.63B | -479.80M | -1.35B | -1.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
665.46 | 72.75B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
636.02 | 38.65B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.99 | 34.69B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
114.50 | 27.45B | 3.30B | -501.07M | 1.03B | -2.1146 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-18-24 | Initiated | Oppenheimer | Outperform |
Aug-16-24 | Initiated | Cantor Fitzgerald | Overweight |
Jun-28-24 | Initiated | Truist | Buy |
May-10-23 | Upgrade | Wedbush | Neutral → Outperform |
Apr-03-23 | Downgrade | Guggenheim | Buy → Neutral |
Jan-27-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
Jan-05-23 | Downgrade | Cowen | Outperform → Market Perform |
Dec-02-22 | Downgrade | BofA Securities | Buy → Neutral |
Oct-31-22 | Downgrade | JP Morgan | Neutral → Underweight |
Oct-31-22 | Downgrade | Wedbush | Outperform → Neutral |
Jul-06-22 | Resumed | Canaccord Genuity | Buy |
Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
Feb-03-22 | Resumed | Guggenheim | Buy |
Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
Nov-16-21 | Downgrade | JP Morgan | Overweight → Neutral |
May-07-21 | Upgrade | BofA Securities | Neutral → Buy |
Apr-23-21 | Resumed | Cowen | Outperform |
Mar-22-21 | Resumed | JP Morgan | Overweight |
Jan-15-21 | Downgrade | BofA Securities | Buy → Neutral |
Nov-09-20 | Reiterated | H.C. Wainwright | Buy |
May-05-20 | Initiated | Barclays | Overweight |
May-01-20 | Initiated | Janney | Buy |
Apr-29-20 | Initiated | Morgan Stanley | Equal-Weight |
Dec-24-19 | Initiated | JP Morgan | Overweight |
Nov-20-19 | Initiated | Guggenheim | Buy |
Sep-04-19 | Initiated | Wedbush | Outperform |
Apr-01-19 | Initiated | H.C. Wainwright | Buy |
Oct-16-18 | Initiated | BTIG Research | Buy |
Oct-16-18 | Initiated | BofA/Merrill | Buy |
View All
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
YMAB Stock Touches 52-Week Low at $5.69 Amid Market Challenges - MSN
When the Price of (YMAB) Talks, People Listen - Stock Traders Daily
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel
Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel
Now Is The Time To Build A Position In Health In Tech Inc (NASDAQ:HIT) - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times
Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex
An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel
A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Let’s Jump Into The SolarBank Corporation (NASDAQ: SUUN) Stock Forecast - Marketing Sentinel
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times
Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World
Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Now Is The Time To Build A Position In NewGenIvf Group Ltd (NASDAQ:NIVF) - Marketing Sentinel
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St
Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn
Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times
Y Mabs Therapeutics Inc Stock (YMAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):